General
Preferred name
PIPAMPERONE
Synonyms
Floropipamide ()
McN-JR 3345 ()
R 3345 ()
Pipamperone hydrochloride ()
R-3345 ()
NSC-759178 ()
Pipaneperone ()
P&D ID
PD000333
CAS
1893-33-0
Tags
natural product
drug
available
Drug Status
investigational
approved
Max Phase
Phase 3
Drug indication
Antipsychotic
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
TOXICITY
Ld50 in rats, 48 mg/kg [L1520].; Prolonged Qtc interval. Monitoring with regular ECGs is recommended [L1525]. ; ; ;
MOA
Pipamperone binds mainly to 5-HT2A receptors, with a nearly equal affinity to D4 receptors and a moderate affinity for 5-HT2C, D2, D3, 1- and 2B-adrenoceptors [A12816].; ; This drug is a selective 5-HT2A, D1 and D4 antagonist [L1516, A32507]. Extrapyramidal adverse effects also appear to be limited in pipamperone treatment compared to traditional antipsychotic medications due to its high receptor selectivity [L1514].; ; Pipamperone has a 15-fold higher affinity for D4 than D2 receptors. It has been suggested that D4 receptors may play a role in the modulation of GABAergic neuronal activity by dopamine [A12816]. ;
PHARMACODYNAMICS
Pipamperone is an antipsychotic medication that has sedative effects, which may be beneficial in the management of agitation and disordered sleep [A32062]. Pipamperone, showing antidopaminergic and anti-serotonergic properties, has been noted for its anti-; agitation effects and for its ability to normalize sleep rhythms in psychiatric patients [A12816]. One study showed that pipamperone increased the expression of D4 (dopaminergic) receptors, explaining its helpfulness in decreasing positive psychotic symptoms, such as delusions and hallucinations [L1524].
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
Compound Sets
13
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMatrix
Guide to Pharmacology
Ki Database
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
ReFrame library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
31
Molecular Weight
375.23
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
7
Ring Count
3
Aromatic Ring Count
1
cLogP
2.59
TPSA
66.64
Fraction CSP3
0.62
Chiral centers
0.0
Largest ring
6.0
QED
0.74
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Member status
member
MOA
5-HT2 Antagonists
Dopamine D2 Antagonists
Dopamine Receptor antagonist
Target
DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR2A
5-HT Receptor
Dopamine Receptor
Indication
schizophrenia
Pathway
GPCR/G protein
Neuronal Signaling
Source data
